Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib)

Bone

Volumn 59, Issue , 2014, Pages 151-161

  El Hoss, J ^a,b   Kolind, M ^a   Jackson, M T ^c   Deo, N ^a,b   Mikulec, K ^a   McDonald, M M ^d   Little, C B ^c   Little, D G ^a,b   Schindeler, A ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cancer; Cartilage remodeling; Endochondral ossification; Fracture healing; Ras MAPK

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AGGRECANASE 2; CELL PROTEIN; COLLAGEN; COLLAGEN TYPE 2A1; COLLAGENASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN ACAN; SCLEROPROTEIN; SELUMETINIB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATE GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALLUS; CALVARIA; CARTILAGE CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENCHONDRAL OSSIFICATION; FEMALE; FEMUR; FRACTURE HEALING; GENE; GENE EXPRESSION; GROWTH PLATE; HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; RUNX2 GENE; TIBIA FRACTURE;

CANCER; CARTILAGE REMODELING; ENDOCHONDRAL OSSIFICATION; FRACTURE HEALING; RAS-MAPK;

ANIMALS; BENZAMIDES; BENZIMIDAZOLES; BONE MARROW CELLS; BONY CALLUS; CARTILAGE; CELL DIFFERENTIATION; CHONDROCYTES; DIPHENYLAMINE; FRACTURE HEALING; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PROTEIN KINASE INHIBITORS; RANK LIGAND; SHEEP; SKULL; X-RAY MICROTOMOGRAPHY;

EID: 84890209397     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.013     Document Type: Article

References (39)

1. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012, 72:2457-2467.
2. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
3. Huynh H., Chow P.K., Soo K.C. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 2007, 6:2468-2476.
4. Henderson Y.C., Chen Y.Y., Frederick M.J., Lai S.Y., Clayman G.L. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 2010, 9:1968-1976.
5. Koup J.R., Liu J., Loi C.-M., Howard C., Van Becelaere K., Przybranowski S., et al. PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model. AACR meeting abstracts 2004 2004, 1248-b.
6. Denton C.L., Gustafson D.L. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol 2011, 67:349-360.
7. Adjei A.A., Cohen R.B., Franklin W., Morris C., Wilson D., Molina J.R., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
8. Guise T.A. Bone loss and fracture risk associated with cancer therapy. Oncologist 2006, 11:1121-1131.
9. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H., Ashley S., Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181.
10. Lefebvre V., Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today 2005, 75:200-212.
11. Goldring M.B., Tsuchimochi K., Ijiri K. The control of chondrogenesis. J Cell Biochem 2006, 97:33-44.
12. Einhorn T.A. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998, S7-21.
13. Schindeler A., McDonald M.M., Bokko P., Little D.G. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 2008, 19:459-466.
14. Ge C., Xiao G., Jiang D., Franceschi R.T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 2007, 176:709-718.
15. Matsushita T., Chan Y.Y., Kawanami A., Balmes G., Landreth G.E., Murakami S. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol 2009, 29:5843-5857.
16. Provot S., Nachtrab G., Paruch J., Chen A.P., Silva A., Kronenberg H.M. A-Raf and B-Raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol Cell Biol 2008, 28:344-357.
17. El-Hoss J., Sullivan K., Cheng T., Yu N.Y.C., Bobyn J.D., Peacock L., et al. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells. J Bone Miner Res 2012, 27:68-78.
18. Schindeler A., Morse A., Harry L., Godfrey C., Mikulec K., McDonald M., et al. Models of tibial fracture healing in normal and Nf1-deficient mice. J Orthop Res 2008, 26:1053-1060.
19. Zhang L., Lee N.J., Nguyen A.D., Enriquez R.F., Riepler S.J., Stehrer B., et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab 2010, 12:591-603.
20. Little C.B., Ghosh P. Variation in proteoglycan metabolism by articular chondrocytes in different joint regions is determined by post-natal mechanical loading. Osteoarthritis Cartilage 1997, 5:49-62.
21. Jackson M.T., Smith M.M., Smith S.M., Jackson C.J., Xue M., Little C.B. Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum 2009, 60:780-791.
22. Schindeler A., Little D.G. Ras-MAPK signaling in osteogenic differentiation: friend or foe?. J Bone Miner Res 2006, 21:1331-1338.
23. Brown A., Carlson T., Loi C.-M., Graziano M. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 2007, 59:671-679.
24. Yeh T.C., Marsh V., Bernat B.A., Ballard J., Colwell H., Evans R.J., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583.
25. Higuchi C., Myoui A., Hashimoto N., Kuriyama K., Yoshioka K., Yoshikawa H., et al. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 2002, 17:1785-1794.
26. Bobick B.E., Kulyk W.M. The MEK-ERK signaling pathway is a negative regulator of cartilage-specific gene expression in embryonic limb mesenchyme. J Biol Chem 2004, 279:4588-4595.
27. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
28. McDonald M.M., Morse A., Mikulec K., Peacock L., Baldock P.A., Kostenuik P.J., et al. MMP driven endochondral fracture union proceeds independently of osteoclast activity. J Bone Miner Res 2013, 28:1550-1560.
29. Colnot C., Thompson Z., Miclau T., Werb Z., Helms J.A. Altered fracture repair in the absence of MMP9. Development 2003, 130:4123-4133.
30. Kosaki N., Takaishi H., Kamekura S., Kimura T., Okada Y., Minqi L., et al. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. Biochem Biophys Res Commun 2007, 354:846-851.
31. Ciuffreda L., Del Bufalo D., Desideri M., Di Sanza C., Stoppacciaro A., Ricciardi M.R., et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. Neoplasia 2009, 11:720-731.
32. Jessen W.J., Miller S.J., Jousma E., Wu J., Rizvi T.A., Brundage M.E., et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013, 123:340-347.
33. Miedlich S.U., Zalutskaya A., Zhu E.D., Demay M.B. Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon ERK1/2 phosphorylation. J Biol Chem 2010, 285:18270-18275.
34. Ranch D., Zhang M.Y.H., Portale A.A., Perwad F. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res 2011, 26:1883-1890.
35. Stickens D., Behonick D.J., Ortega N., Heyer B., Hartenstein B., Yu Y., et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004, 131:5883-5895.
36. Little C.B., Barai A., Burkhardt D., Smith S.M., Fosang A.J., Werb Z., et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733.
37. Kirkwood J.M., Bastholt L., Robert C., Sosman J., Larkin J., Hersey P., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012, 18:555-567.
38. Wang J.Y., Wilcoxen K.M., Nomoto K., Wu S. Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem 2007, 7:1364-1378.
39. Boasberg P.D., Redfern C.H., Daniels G.A., Bodkin D., Garrett C.R., Ricart A.D. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 2011, 68:547-552.